Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 41.94B |
| Revenue (ttm) | 10.90B |
| Net Income (ttm) | 3.48B |
| Shares Out | n/a |
| EPS (ttm) | 30.52 |
| PE Ratio | 12.04 |
| Forward PE | 13.77 |
| Dividend | 0.70 (0.12%) |
| Ex-Dividend Date | May 20, 2025 |
| Volume | 559 |
| Average Volume | 555 |
| Open | 551.06 |
| Previous Close | 546.86 |
| Day's Range | 539.13 - 551.06 |
| 52-Week Range | 545.42 - 998.57 |
| Beta | n/a |
| RSI | 45.96 |
| Earnings Date | Apr 29, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 mil...
Price Over Earnings Overview: Regeneron Pharmaceuticals
In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) price is at $563.91, after a 0.97% increase. However, over the past month, the stock fell by 2.22% , and in the past year,...
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03) . The company reported quarterly sales of $594....
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen Inc. (NASDAQ: BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52 . The c...
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea
Federal court allows Medicare overcharge case against Regeneron over Eylea pricing to proceed. Read more here.
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the...
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma
Regeneron Shares Are Up Today: What's Going On?
Shares of Regeneron Pharmaceuticals are trading higher Wednesday ... Full story available on Benzinga.com
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82 . The company reported sa...
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2185864749-03325c33af8d48b7bdf922f2cc74c34d.jpg)
Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates
Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that m...
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
These are the stocks posting the largest moves in midday trading.
Regeneron projects pivotal data readouts for multiple programs in 2025
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More
U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and t...
Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report
Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.
Regeneron Stock Plummets After Earnings Miss
Regeneron drops as Eylea drives Q1 miss
Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster drug Eylea. Read more here.
Regeneron Pharma's first-quarter results miss on lower Eylea demand
Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket tra...
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
Regeneron Pharmaceuticals misses Q1 estimates
Regeneron Reports First Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.
Earnings Scheduled For April 29, 2025
Companies Reporting Before The Bell • First Commonwealth (NYSE: FCF) is estimated to report quarterly earnings at $0.32 per share on revenue of $117.60 million. • CommVault Systems (NASDAQ: CVLT) is...